PharmaCyte Biotech, Inc. (PMCB) financial statements (2021 and earlier)

Company profile

Business Address 23046 AVENIDA DE LA CARLOTA, SUITE 600
LAGUNA HILLS, CA 92653
State of Incorp. NV
Fiscal Year End April 30
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

1/31/2021
TTM
4/30/2020
4/30/2019
4/30/2018
4/30/2017
4/30/2016
4/30/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments3111323
Cash and cash equivalents3111323
Other undisclosed current assets0000000
Total current assets:3111423
Noncurrent Assets
Long-term investments and receivables2222222
Long-term investments2222222
Intangible assets, net (including goodwill)4444444
Intangible assets, net (excluding goodwill)4444444
Other noncurrent assets0000000
Total noncurrent assets:5555555
TOTAL ASSETS:8666978
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities1111101
Accounts payable0000000
Accrued liabilities0110000
Employee-related liabilities      0
Debt00     
Derivative instruments and hedges, liabilities      0
Other undisclosed current liabilities     01
Total current liabilities:1111112
Noncurrent Liabilities
Long-term debt and lease obligation00     
Long-term debt, excluding current maturities00     
Total noncurrent liabilities:00     
Total liabilities:1111112
Stockholders' equity
Stockholders' equity attributable to parent8556876
Common stock0000000
Additional paid in capital114109105102979185
Accumulated other comprehensive income (loss)(0)(0)(0)(0)000
Accumulated deficit(106)(104)(100)(96)(89)(85)(80)
Total stockholders' equity:8556876
TOTAL LIABILITIES AND EQUITY:8666978

Income statement (P&L) ($ in millions)

1/31/2021
TTM
4/30/2020
4/30/2019
4/30/2018
4/30/2017
4/30/2016
4/30/2015
Other income (0)00 0
Gross profit:  00 0 
Operating expenses(3)(4)(4)(7)(4)(6)(14)
Other undisclosed operating income (loss) 0(0)(0) (0) 
Operating loss:(3)(4)(4)(7)(4)(6)(14)
Nonoperating income (expense)
(Other Nonoperating Income (Expense))
(0)(0)00(0)03
Interest and debt expense(0)(0)  (0)(0)3
Other undisclosed loss from continuing operations before equity method investments, income taxes(0)      
Loss from continuing operations before income taxes:(3)(4)(4)(7)(4)(6)(8)
Income tax benefit      1
Loss before gain (loss) on sale of properties:(3)(4)(4)(7)(4)(6)(7)
Other undisclosed net income0      
Net loss:(3)(4)(4)(7)(4)(6)(7)
Other undisclosed net income (loss) attributable to parent00  00(4)
Net loss attributable to parent:(3)(4)(4)(7)(4)(6)(11)
Preferred stock dividends and other adjustments(0)      
Net loss available to common stockholders, diluted:(3)(4)(4)(7)(4)(6)(11)

Comprehensive Income ($ in millions)

1/31/2021
TTM
4/30/2020
4/30/2019
4/30/2018
4/30/2017
4/30/2016
4/30/2015
Net loss:(3)(4)(4)(7)(4)(6)(7)
Other comprehensive income (loss)0(0)(0)(0)0(0)0
Comprehensive loss:(3)(4)(4)(7)(4)(6)(7)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent00  00(4)
Comprehensive loss, net of tax, attributable to parent:(3)(4)(4)(7)(4)(6)(11)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: